Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses of diabetic patients from the phase II CHRONOS-1 study.

被引：1
|
作者：
Dreyling, Martin H.
Leppa, Sirpa
Comeau, Terrance
Kosinova, Marina
Lenz, Georg
Nagler, Arnon
Heo, Dae Seog
Oh, Sung Yong
Huang, Liping
Wirtz, Oliver
Miriyala, Ashok
Garcia-Vargas, Jose E.
Childs, Barrett H.
Zinzani, Pier Luigi
机构：
[1] Klin Univ Munchen LMU, Medizin Klin & Poliklin 3, Munich, Germany
[2] Helsinki Univ Cent Hosp Canc Ctr, Helsinki, Finland
[3] St Johns Hosp, St John, NB, Canada
[4] Kemerovo Reg Reg Clin Hosp, Kemerovo, Russia
[5] Munster Univ Clin, Translat Oncol Med Clin, Munster, Germany
[6] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel
[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[8] Dong A Univ Coll Med, Dept Internal Med, Busan, South Korea
[9] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA
[10] Bayer AG, Pharmaceut Div, Wuppertal, Germany
[11] Univ Bologna, Inst Hematol L E A Seragnoli, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.7570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7570
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
    H Saito
    D Maruyama
    A M Maeshima
    S Makita
    H Kitahara
    K Miyamoto
    S Fukuhara
    W Munakata
    T Suzuki
    Y Kobayashi
    H Taniguchi
    K Tobinai
    Blood Cancer Journal, 2015, 5 : e362 - e362
  • [42] Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
    Saito, H.
    Maruyama, D.
    Maeshima, A. M.
    Makita, S.
    Kitahara, H.
    Miyamoto, K.
    Fukuhara, S.
    Munakata, W.
    Suzuki, T.
    Kobayashi, Y.
    Taniguchi, H.
    Tobinai, K.
    BLOOD CANCER JOURNAL, 2015, 5 : e362 - e362
  • [43] Outcomes and prognostic factors of patients diagnosed with relapsed/refractory primary B-cell lymphoma: A retrospective study.
    Dumke, Henry
    Phillips, Tycel Jovelle
    Kaminski, Mark S.
    Carty, Shannon
    Wilcox, Ryan A.
    Sano, Dahlia
    Kandarpa, Malathi
    Polk, Avery
    Karimi, Yasmin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
    Graf, Solomon A.
    Cassaday, Ryan D.
    Morris, Karolyn K.
    Behnia, Sanaz
    Wu, Qian Vicky
    Voutsinas, Jenna M.
    Lynch, Ryan C.
    Krakow, Elizabeth
    Rasmussen, Heather A.
    Chauncey, Thomas R.
    Kanan, Sandra
    Soma, Lorinda A.
    Smith, Stephen D.
    Gopal, Ajay K.
    BLOOD, 2019, 134
  • [45] Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study
    Graf, Solomon A.
    Cassaday, Ryan D.
    Morris, Karolyn K.
    Rasmussen, Heather A.
    Becker, Pamela S.
    Chauncey, Thomas R.
    Kanan, Sandra
    Soma, Lorinda A.
    Smith, Stephen D.
    Gopal, Ajay K.
    BLOOD, 2018, 132
  • [46] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ohmachi, Ken
    Niitsu, Nozomi
    Uchida, Toshiki
    Kim, Seok Jin
    Ando, Kiyoshi
    Takahashi, Naoki
    Takahashi, Naoto
    Uike, Naokuni
    Eom, Hyeon Seok
    Chae, Yee Soo
    Terauchi, Takashi
    Tateishi, Ukihide
    Tatsumi, Mitsuaki
    Kim, Won Seog
    Tobinai, Kensei
    Suh, Cheolwon
    Ogura, Michinori
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
  • [47] Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma
    Pinnix, Chelsea C.
    Dabaja, Bouthaina S.
    Gunther, Jillian R.
    Fang, Penny
    Wu, Susan
    Ahmed, Sairah
    Steiner, Raphael E.
    Nair, Ranjit
    Strati, Paolo
    Westin, Jason
    Fayad, Luis
    Iyer, Swami P.
    Rodriguez, Maria Alma
    Lee, Hun Ju
    Samaniego, Felipe
    Chihara, Dai
    Jain, Preetesh
    Feng, Lei
    Flowers, Christopher R.
    Neelapu, Sattva S.
    Nastoupil, Loretta J.
    BLOOD, 2022, 140 : 3741 - 3743
  • [48] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Kim, W. S.
    Ando, K.
    Niitsu, N.
    Ogura, M.
    Takahashi, N.
    Uike, N.
    Eom, H. Seok
    Chae, Y. S.
    Tobinai, K.
    Terauchi, T.
    Tateishi, U.
    Tatsumi, M.
    Suh, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [49] Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL)
    Assouline, Sarit
    Budde, Lihua Elizabeth
    Chavez, Julio C.
    Diefenbach, Catherine S.
    Dorritie, Kathleen Anne
    Ghosh, Nilanjan
    Olszewski, Adam J.
    Lossos, Izidore S.
    Mehta, Amitkumar
    Modi, Dipenkumar
    Naik, Seema
    Smith, Stephen Douglas
    Makadia, Sneha
    Pham, Song
    Wu, Hao
    Batlevi, Connie Lee
    To, Iris
    Wei, Michael C.
    Kamdar, Manali
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma
    Liu, Weiping
    Ping, Lingyan
    Xie, Yan
    Sun, Yingli
    Du, Tingting
    Niu, Yi
    Cisternas, Galia
    Huang, Funan
    Garcia-Vargas, Jose
    Childs, Barrett H.
    Mehra, Aruna
    Reschke, Susanne
    Wang, Xiaopei
    Song, Yuqin
    Zhu, Jun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (06) : 825 - 831
12345